Formulates nicotine-based vapor products. Markets vapor products to consumers. Now — the numbers.
This is an established company with proven profits.
No real growth (-1% a year). Red columns mark years that ended in a loss.
The gap is $1.7M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 10.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 22% — still a thick cushion, though costs have been eating into it lately.
Over the last 12 months, company executives reported 18 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.16. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 4 years, sales fell about 1% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.